Zydelig - (100 mg and 150 mg ; Tablets)

Generic Name	Idelalisib	Innovator	Gilead
Dosage	100 mg and 150 mg ; Tablets	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	Zydelig is a kinase inhibitor indicated for the treatment of patients with: • Relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities. • Relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patients who have received at least two prior systemic therapies. • Relapsed small lymphocytic lymphoma (SLL) in patients who have received at least two prior systemic therapies.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
*****	*** \ *********	*** **, ****	*******	****	******* *** **** *** *** ****

Chronology Of Events